Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096161 · ClinicalTrials.gov registry record · Phase 2
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00096161 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 36 participants.
The verdict
NCT00096161, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant. Giving pentostatin and an infusion of the donor's T cells (donor lymphocyte infusion) after a donor stem cell transplant may stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before donor lymphocyte infusion may stop this from happening.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Cyclosporine
- DRUG Pentostatin
- BIOLOGICAL Therapeutic Allogeneic Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096161
The ClinicalTrials.gov registry entry for NCT00096161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00096161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096161 about?
NCT00096161 is a clinical study titled "Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant". This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant. Giving pentostatin and an infusion of the donor's T cells (donor lymphocyte infusion) after a donor stem cell transplant may stop the patient...
What is the current status of trial NCT00096161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2003-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00096161?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Cyclosporine (DRUG), Pentostatin (DRUG), Therapeutic Allogeneic Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00096161?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.